-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎Editor of WuXi AppTec's content team On July 7, 2021, Moderna announced that the Phase 1/2 clinical trial of its research vaccine mRNA-1010 has completed the first batch of subjects vaccinated
.
mRNA-1010 is a 4-valent seasonal influenza mRNA candidate vaccine, targeting four seasonal influenza virus strains recommended by the World Health Organization (WHO), including influenza A virus strains H1N1 and H3N2, and influenza B virus strain Yamagata And Victoria
.
The press release states that it is Moderna's first seasonal flu vaccine candidate product that has entered clinical development
.
This phase 1/2 clinical trial aims to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1010 in healthy adults 18 years and older, and plans to enroll about 180 subjects into the group
.
The epidemic of seasonal influenza causes respiratory diseases and places a huge burden on the healthcare system
.
According to WHO estimates, there are about 3 million to 5 million severe cases of influenza worldwide each year, and about 290,000 to 650,000 deaths from influenza-related respiratory diseases occur
.
However, the current flu vaccines are only about 40-60% effective, and their formulations were decided 6-9 months before the planned use of the vaccine
.
In addition, most of the licensed influenza vaccines use egg-based culture technology, which may allow the vaccine virus to produce unexpected antigenic changes
.
▲The potential advantages of mRNA vaccines (picture source: Moderna official website) "Seasonal influenza vaccine candidate products will become an important part of our future respiratory combined vaccines
.
"Moderna CEO Mr.
Stéphane Bancel said, "Respiratory combined vaccine is one of the important pillars of our mRNA vaccine strategy
.
We believe that the advantages of mRNA vaccines include the ability to combine different antigens, prevent multiple viruses, and have the ability to quickly respond to the evolution of respiratory viruses (such as influenza virus, new coronavirus and respiratory syncytial virus)
.
Our vision is to develop an mRNA combination vaccine, so that people only need to vaccinate once in each autumn, which can provide high-efficiency protection against the most threatening respiratory viruses
.
"Reference: [1] Moderna Announces First Participant Dosed in Phase 1/2 Study of Its Quadrivalent Seasonal Flu mRNA Vaccine.
Retrieved July 7, 2021, from https://investors.
modernatx.
com/news-releases/news-release -details/moderna-announces-first-participant-dosed-phase-12-study-its Note: This article aims to introduce the progress of medical and health research, not a treatment plan recommendation
.
If you need treatment plan guidance, please go to a regular hospital
.
.
mRNA-1010 is a 4-valent seasonal influenza mRNA candidate vaccine, targeting four seasonal influenza virus strains recommended by the World Health Organization (WHO), including influenza A virus strains H1N1 and H3N2, and influenza B virus strain Yamagata And Victoria
.
The press release states that it is Moderna's first seasonal flu vaccine candidate product that has entered clinical development
.
This phase 1/2 clinical trial aims to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1010 in healthy adults 18 years and older, and plans to enroll about 180 subjects into the group
.
The epidemic of seasonal influenza causes respiratory diseases and places a huge burden on the healthcare system
.
According to WHO estimates, there are about 3 million to 5 million severe cases of influenza worldwide each year, and about 290,000 to 650,000 deaths from influenza-related respiratory diseases occur
.
However, the current flu vaccines are only about 40-60% effective, and their formulations were decided 6-9 months before the planned use of the vaccine
.
In addition, most of the licensed influenza vaccines use egg-based culture technology, which may allow the vaccine virus to produce unexpected antigenic changes
.
▲The potential advantages of mRNA vaccines (picture source: Moderna official website) "Seasonal influenza vaccine candidate products will become an important part of our future respiratory combined vaccines
.
"Moderna CEO Mr.
Stéphane Bancel said, "Respiratory combined vaccine is one of the important pillars of our mRNA vaccine strategy
.
We believe that the advantages of mRNA vaccines include the ability to combine different antigens, prevent multiple viruses, and have the ability to quickly respond to the evolution of respiratory viruses (such as influenza virus, new coronavirus and respiratory syncytial virus)
.
Our vision is to develop an mRNA combination vaccine, so that people only need to vaccinate once in each autumn, which can provide high-efficiency protection against the most threatening respiratory viruses
.
"Reference: [1] Moderna Announces First Participant Dosed in Phase 1/2 Study of Its Quadrivalent Seasonal Flu mRNA Vaccine.
Retrieved July 7, 2021, from https://investors.
modernatx.
com/news-releases/news-release -details/moderna-announces-first-participant-dosed-phase-12-study-its Note: This article aims to introduce the progress of medical and health research, not a treatment plan recommendation
.
If you need treatment plan guidance, please go to a regular hospital
.
